Nautilus Biotechnology, Inc.

NASDAQ:NAUT

Biotechnology

Healthcare
$2.43 +2.06%

+$0.05 today

Market cap
$309.51M
Beta
0.75
P/E (TTM)
-4.9
EPS (TTM)
-$0.45
52W Low $0.62High $4.31

Volume 4.55M

Average 0.40M

NAUT Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Nautilus Biotechnology, Inc.NASDAQ: NAUT

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was -$1.48M, compared with -$1.63M a year earlier. Trailing-twelve-month gross profit was -$6.32M.

Context

  • Gross profit grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$1.48M or moves back toward the trailing-twelve-month quarterly average of -$1.58M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.48M+7.1% QoQ
Last fiscal yearDec 2025
-$6.47M-1.8% YoY
LTMMar 2026
-$6.32M+43.5% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.2%——
1 year-1.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(6.47M) USD
Year-over-year change
-1.8%

Gross Profit vs competitors

How NAUT compares with its peers on the latest reported figures

  • NAUT's LTM Mar 2026 gross profit of -$6.32M is the 10th highest of the 11 companies compared; the peer median is $3.3M.
  • Its year-over-year change of +43.5% is the 3rd highest of 9, against a peer median of -71.3%.
NAUT Competitors Peer median
Gross Profit for NAUT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$68M +5.5%-11.0%98.3%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$54.91M +621.8%—77.2%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$41.35M -69.4%-32.2%91.2%
PYXSPyxis Oncology, Inc.LTM Mar 2026$13.83M ——99.8%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$6.28M -73.3%+12.8%22.3%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$326K +115.4%—144.9%
SGMTSagimet Biosciences Inc.LTM Mar 2026$0 ———
ZURAZura Bio LimitedLTM Mar 2026-$16K -220.0%——
IMRXImmuneering CorporationLTM Mar 2026-$793.21K -354.2%——
NAUTNautilus Biotechnology, Inc.LTM Mar 2026-$6.32M +43.5%——
HUMAHumacyte, Inc.LTM Mar 2026-$15.09M -917.5%—748.5%
Peer median (excluding NAUT) $3.3M-71.3%-11.0%98.3%

Competitors are the stored peer set for NAUT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue2.84M3.42M5.71M6.35M6.47M
Gross Profit(2.84M)(3.42M)(5.71M)(6.35M)(6.47M)
Gross Margin—————
Research & Development26.51M36.46M47.25M50.48M41.11M
Selling, General & Admin21.15M23.75M28.9M31M25.73M
Operating Expenses47.66M60.2M70.45M75.12M60.37M
Depreciation & Amortization2.84M3.42M1.85M6.35M6.47M
EBITDA(47.47M)(54.51M)(61.83M)(64.43M)(52.54M)
EBITDA Margin—————
Operating Income(50.5M)(63.62M)(76.15M)(81.48M)(66.84M)
Operating Margin—————
Interest Income329K5.82M12.55M10.78M7.87M
Interest Expense05.82M000
Other Income / Expenses183K5.69M12.48M10.7M7.84M
Income Before Tax(50.32M)(57.92M)(63.68M)(70.78M)(59M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(50.32M)(57.92M)(63.68M)(70.78M)(59M)
Net Margin—————
EPS (Basic)(0.60)(0.46)(0.51)(0.56)(0.47)
EPS (Diluted)(0.60)(0.46)(0.51)(0.56)(0.47)
Weighted Avg Shares84.46M124.59M124.92M125.43M126.26M
Weighted Avg Shares (Diluted)84.46M124.59M124.92M125.43M126.26M

Nautilus Biotechnology, Inc.

NASDAQ:NAUT

Intrinsic Alpha fair value

Locked

Current Price

$2.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.